Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study.
Aged
Aged, 80 and over
Albumins
/ administration & dosage
Antineoplastic Agents, Phytogenic
/ administration & dosage
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Paclitaxel
/ administration & dosage
Retrospective Studies
Salvage Therapy
Small Cell Lung Carcinoma
/ drug therapy
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
15
3
2019
Statut:
ppublish
Résumé
Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel (PTX) in R/R SCLC patients.A single-institute retrospective chart review was conducted. The primary endpoint was overall survival (OS), whereas the secondary endpoints were progression-free survival (PFS), overall response rate, disease control rate (DCR), and safety.Thirty-one patients (median age, 69 [range, 56-80] years) were analyzed. The median follow-up period was 122 (range, 28-1121) days. The median OS and PFS were 4.4 and 2.2 months, respectively. Adverse events of grade 3 or higher, other than hematological toxicity, were febrile neutropenia and neuropathy. Multivariate analyses identified the following independent predictors of poor OS: performance status and lactate dehydrogenase at the upper limit of normal.PTX monotherapy showed moderate efficacy with acceptable toxicity in heavily treated patients with R/R SCLC patients.
Identifiants
pubmed: 30817634
doi: 10.1097/MD.0000000000014758
pii: 00005792-201903010-00074
pmc: PMC6831182
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Antineoplastic Agents, Phytogenic
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14758Références
Ann Oncol. 2015 May;26(5):908-914
pubmed: 25688059
Br J Cancer. 1998;77(2):347-51
pubmed: 9461009
J Clin Oncol. 2017 Apr 20;35(12):1281-1287
pubmed: 28135143
J Clin Oncol. 2009 May 20;27(15):2530-5
pubmed: 19349543
Lancet. 2005 Oct 15-21;366(9494):1385-96
pubmed: 16226617
Medicine (Baltimore). 2017 Oct;96(42):e8176
pubmed: 29049199
Lung Cancer. 2012 Aug;77(2):383-8
pubmed: 22551892
Lung Cancer. 2015 Jul;89(1):61-5
pubmed: 26004087
Med Arch. 2014;68(2):83-5
pubmed: 24937927
Medicine (Baltimore). 2017 Sep;96(35):e7884
pubmed: 28858103
J Clin Oncol. 2014 Dec 10;32(35):4012-9
pubmed: 25385727
N Engl J Med. 2002 Jan 10;346(2):85-91
pubmed: 11784874
Oncotarget. 2017 Jan 31;8(5):8657-8669
pubmed: 28055965
Immunotherapy. 2016 Jun;8(7):821-37
pubmed: 27349981
J Clin Oncol. 2006 Dec 1;24(34):5441-7
pubmed: 17135646
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
Eur J Cancer Clin Oncol. 1987 Sep;23(9):1409-11
pubmed: 2824211
Anticancer Res. 2006 Jan-Feb;26(1B):777-81
pubmed: 16739353
Expert Opin Investig Drugs. 2018 Jul;27(7):569-572
pubmed: 29958097
Ann Transl Med. 2017 Sep;5(17):361
pubmed: 28936455
J Clin Oncol. 2008 Nov 20;26(33):5401-6
pubmed: 18854562
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313